@article {Markowski1270, author = {Mark C. Markowski and Pedro Isaacsson Velho and Mario A. Eisenberger and Martin G. Pomper and Kenneth J. Pienta and Michael A. Gorin and Emmanuel S. Antonarakis and Samuel R. Denmeade and Steven P. Rowe}, title = {Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy}, volume = {62}, number = {9}, pages = {1270--1273}, year = {2021}, doi = {10.2967/jnumed.120.259226}, publisher = {Society of Nuclear Medicine}, abstract = {Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT. Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL{\textendash}avid lesion. Results: Three of 6 (50\%) patients had progression on 18F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on 18F-DCFPyL PET/CT. For the 3 patients who did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/62/9/1270}, eprint = {https://jnm.snmjournals.org/content/62/9/1270.full.pdf}, journal = {Journal of Nuclear Medicine} }